Introduction
The evolution of the tumor and the outcome of cancer metastatic spread is regulated by circulating blood platelets.
1,2
Cancer cells stimulate platelet activation and aggregation, and, by interacting with cancer cells in the bloodstream, platelets generate a protective shield against shear stresses and immune system. 3, 4 Activated platelets protect circulating cancer cells also by downregulating NK cells response through the release of TGF-β. 5 Moreover, platelets favor cancer cell adhesion to the vessel wall and subsequent extravasation.
4,6
Importantly, platelet depletion or inhibition are associated with reduced cancer spread, both in mice and in humans.
cells promoting different biological responses. 7, 8 Some studies have proposed that PMPs can interact with cancer cells to induce their activation. In particular, PMPs can regulate cancer spread by supporting cell invasion, promoting angiogenesis, and potentiating metastasis. 9 Platelets are the main source of bloodborne microparticles and the concentration of PMPs is elevated in many types of cancerous malignancies, such as skin, lung, gastric, colorectal, and breast cancers. [10] [11] [12] [13] The mechanisms supporting the increase of circulating PMPs in cancer patients are poorly understood. In particular, it is still unknown whether cancer cells, by interacting with platelets, can directly induce the release of PMPs, and whether cancer cell-induced PMPs can operate any feedback regulation on cancer cells phenotype. The aim of this work was to investigate the complex relationship between cancer cells and platelets focusing on the possible role of PMPs in the support of platelets to breast cancer metastasis. To this purpose, two commonly used breast cancer cell lines (MDA-MB-231 and MCF7) were selected to investigate whether these cells induce the release of microparticles from platelets. The PMPs obtained from platelets exposed to cancer cells were quantified and their ability to regulate the aggressiveness of the same cancer cells that induced their release was analyzed. The collected results demonstrate that breast cancer cells are actually able to potentiate their own invasive phenotype by inducing the release of prometastatic PMPs.
Materials and Methods

Platelet Isolation and Cancer Cell Maintenance
Human blood platelets were purified from fresh buffy-coat bags using a well-standardized protocol with minor modifications.
14 Briefly, buffy-coat was diluted by adding one-third volume of a 1:9 mixture of ACD (152 mM sodium citrate, 130 mM citric acid, and 112 mM glucose) and HEPES buffer (10 mM HEPES, 137 mM NaCl, 2.9 mM KCl, and 12 mM NaHCO 3 , pH 7.4). Diluted blood was divided in 5 mL aliquots, centrifuged at 120g for 15 minutes at room temperature and the supernatant was collected. Apyrase (0.2 U/mL) and PGE 1 (1 µM) were added, and platelets were recovered by centrifugation at 750g for 15 minutes, washed with 5 mL of PIPES buffer (20 mM PIPES and 136 mM NaCl, pH 6.5), and finally resuspended gently in HEPES buffer supplemented with 1 mM CaCl 2 , 0.5 mM MgCl 2 , and platelet poor plasma (0.05% v/v).
MDA-MB-231 and MCF7 cells were provided by Dr. Livia Visai (Department of Molecular Medicine, University of Pavia) and Dr. Maria Grazia Bottone (Department of Biology and Biotechnology, University of Pavia), respectively. Upon thawing, MCF7 and MDA-MB-231 cells were maintained in DMEM; supplemented with 10% FBS, 2 mM L-glutamine, 100 unit/mL penicillin, and 100 µg/mL streptomycin; split every 2 days; and used for the experiments within 1 month. For the platelet stimulation experiments, cancer cells were washed with PBS, and then detached by incubation for 15 minutes at 37°C with 5 mM EDTA in PBS and gentle pipetting. Cells were recovered by centrifugation and finally resuspended at the concentration of 1 Â 10 7 /mL in HEPES buffer containing 5.5 mM glucose and kept at 37°C until use.
Analysis of PMPs Release Induced by Cancer Cells
Purified platelets (3 Â 10 8 platelets/mL) were incubated with cancer cells (5 Â 10 4 cells/mL) for 30 minutes at 37°C under constant stirring. As a positive control, platelet samples were stimulated with the physiological agonist thrombin (0.2 U/mL). Tumor cell-induced platelet aggregation was monitored in a Born aggregometer. In some experiments, platelets were labeled with 3 µg/mL of carboxyfluorescein succinimidyl ester (CFSE) for 10 minutes, before incubation with tumor cells. For PMPs isolation, platelets and cancer cells were pelleted by centrifugation (750g, 15 minutes). The supernatant was recovered, and either directly analyzed by flow cytometry and fluorescence microscopy or further centrifuged at 20,000g for 90 minutes to collect PMPs, which were quantified for protein content by BCA assay and used for subsequent experiments. Protein content of the different preparations was used to calibrate the amount of PMPs added to cells in all the subsequent experiments. 
Analysis of PMPs Interaction with Cancer Cells
Cell Viability
Cell viability was assessed by using the colorimetric MTT assay. Cancer cells were seeded in 96-well plate at a density of 5 Â 10 3 cells/well the day before the experiment. Increasing amounts of PMPs were incubated with cells for 24 hours at 37°C. MTT solution was added at the final concentration of 0.5 mg/mL and plate was incubated at 37°for 3 additional hours. Finally, dimethyl sulfoxide was added and, after 10 minutes at room temperature, plate was read using a test wavelength of 570 nm and a reference wavelength of 650 nm.
Migration and Invasion Assay
The effect of PMPs on migration and invasiveness of cancer cells was evaluated using Falcon cell culture inserts (8-µm pore size) positioned in a 24-well plate. For the invasion assays, the upper side of the insert was coated with 0.1 mL of Matrigel (50 µg/mL) following the manufacturer's indications. Cancer cells were serum starved for 6 hours and then resuspended DMEM added of 2 mM L-glutamine, 100 unit/mL penicillin, and 100 µg/mL streptomycin and 0.5% FBS. Cell samples were either left untreated or treated with increasing amount of the different PMP preparations and then transferred inside the inserts. Complete medium, containing 10% FBS, was added to lower chamber. Upon 18 hours, cells that moved through the
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porous membrane were stained with 0.5% crystal violet and counted at 20Â microscope magnification.
SDS-PAGE and Immunoblotting
The analysis of protein expression and phosphorylation was performed by SDS-PAGE followed by immunoblotting as described. 15 The following antibodies were used: anti-phosphoAkt (Ser473), anti-phospho-Erk (Tyr202/204), anti-phospho-MLC (Ser19), anti-phospho-p38MAPK (Thr180/Tyr182; Cell Signaling), and anti-GAPDH (Santa Cruz). Quantification of band intensity was performed by computer-assisted densitometric scanning using ImageJ Version 1.42 software.
Statistics
All the reported figures are representative of at least three experiments and data were analyzed by t-test (for comparisons of two groups) or one-way ANOVA with the Bonferroni post-test (for multiple comparisons).
Results
Cancer Cell-Induced Release of PMPs
Elevated amounts of circulating PMPs are a common feature in breast cancer patients, often associated with an advanced metastatic stage. 13 To investigate the mechanism of cancerassociated increase of PMPs, we investigated whether, in vitro, breast cancer cells themselves directly stimulate the release of microparticles from human platelets. To this purpose, we used two well-characterized metastatic breast cancer cell lines from pleural effusion: the more aggressive, triple-negative, mesenchymal-like MDA-MB-231 cells, and the less aggressive estrogen and progesterone receptors positive, epithelial-like MCF7 cells. Both MDA-MB-231 and MCF7 cells were able to activate platelets and caused a comparable irreversible platelet aggregation within 30 minutes (►Fig. 1A). Differently from thrombin, a prolonged lag time was observed, as documented also for other cancer cell lines. 16, 17 The ability of breast cancer cells to stimulate the release of PMPs was investigated by exposing platelets labeled with the fluorescent probe CFSE to MDA-MB-231 or MCF7 cells for 30 minutes. Untreated and thrombin-stimulated platelets were used as negative and positive controls, respectively. Upon removal of platelets and cancer cells by centrifugation, the supernatants were spotted on glass coverslips and analyzed by fluorescence microscopy. ►Fig. 1B shows that, as seen with thrombin, both MDA-MB-231 and MCF7 cells caused an evident release of fluorescently labeled microparticles from platelets. Although platelets are small cells, with an average diameter of 2 to 4 µm, the size of labeled microparticles recovered from the supernatant was clearly smaller, and was consistent with that expected for PMPs (up to 1 µm), thus confirming that no contaminant cells remained upon centrifugation. In reverse experiments, unlabeled platelets were incubated with CFSE-labeled breast cancer cells, but no fluorescent microparticles were detected in the supernatant (►Fig. 1C), demonstrating that, when co-cultured, breast cancer cells induce the release of microparticles from platelets, but not vice versa. Accordingly, immunoblotting analysis revealed that released microparticles were CD41 positive (data not shown). 
Cancer Cell-Induced PMPs Differently Interact with Cancer Cells
Since microparticles released upon activation of platelets with physiological agonists such as thrombin are able to interact with cancer cells, 18, 19 we investigated whether MCF7-induced and MDA-MB-231-induced PMPs were also capable to subsequently interact with the same cell types that promoted their release. Equal amounts of fluorescent PMPs, produced by CFSElabeled platelets treated with either MCF7 or MDA-MB-231 cells (indicated as MCF7-induced and MDA-MB-231-induced, respectively), were incubated for 18 hours with both types of breast cancer cells. More than 90% of MDA-MB-231 cells were found to be surrounded by both MCF7-induced and MDA-MB-231-induced PMPs. By contrast, less than 3% of MCF7 cells were associated with either type of PMPs (►Fig. 2A). To compare the ability of MDA-MB-231 cells to associate with the two types of PMPs, we measured the cell-associated fluorescence. We found that MDA-MB-231 cells were equally able to interact with MCF7-induced or MDA-MB-231-induced PMPs, both at a short or at a late time (►Fig. 2A). These results indicate that although MCF7 cells can efficiently aggregate whole platelets to support PMPs release, they are unable to subsequently interact with released PMPs. By contrast MDA-MB-231 cells efficiently interact with PMPs originated by platelets stimulated with both cell lines.
Previous studies have indicated a role for integrin αIIbβ3 and P-selectin in platelet interaction with cancer cells. 20, 21 To get further insights into the mechanism of PMPs interaction with MDA-MB-231 cells, we analyzed the effect of the integrin αIIbβ3 antagonist peptide RGDS and of the P-selectin blocking antibody CLB/thromb/6 (NOVUS Biologicals). ►Fig. 2B shows that neither integrin αIIbβ3 nor P-selectin inhibition reduced the interaction of MDA-MB-231 cells with either type of PMPs. By contrast, we found that this interaction was dose
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dependently inhibited by heparin, suggesting the implication of a still unknown carbohydrate-recognizing mechanism (►Fig. 2B).
Confocal microscopy analysis revealed that MDA-MB-231-associated fluorescent PMPs were localized on the same focal plane as cell nuclei, indicating that both MCF7-and MDA-MB-231-induced PMPs were internalized. This process occurred rapidly, being already detectable after 4 hours of incubation (►Fig. 2C). These results indicate that the two different breast cancer cell lines, both of which are able to activate platelets to release PMPs, are differently targeted by the circulating PMPs that they have induced. Release of Prometastatic PMPs Induced by Breast Cancer Cells Zarà et al. e159
PMPs Modulate Migration and Invasiveness of MDA-MB-231 Cells
We next investigated the functional consequence of PMPs interaction and internalization by MDA-MB-231 cells. Neither type of PMPs displayed cytotoxic effects on either MDA-MB-231 or MCF7 cells, as no alteration of cell viability was observed upon incubation with increasing amounts of PMPs (0-50 µg/mL; ►Fig. 3A). The slight increase observed when MDA-MB-231 cells were incubated with MDA-MB-231-induced PMPs was not statistically significant. To investigate whether interaction with PMPs caused activation of MDA-MB-231 cells, we analyzed the phosphorylation of selected signaling proteins. Cells were incubated with identical amount of PMPs, as determined by protein content assessment, at a final PMPs concentration of 30 µg/mL. We found that only MDA-MB-231-induced, but not MCF7-induced, PMPs significantly stimulated the phosphorylation of p38MAPK and myosin light chain (MLC) in MDA-MB-231 cells (►Fig. 3B). This effect was selective, as phosphorylation of other intracellular signaling molecules, such as Akt or ERK, was unaffected. Consistent with the previously shown inability to bind and internalize PMPs, protein phosphorylation in MCF7 cells was unaffected by the addition of both types of PMPs (►Fig. 3C).
It is known that p38MAPK and MLC are implicated in the control of cell motility. 22 We found that PMPs induced by MDA-MB-231 cells, but not those induced by MCF7 cells, strongly and dose-dependently potentiated the migration of MDA-MB-231 cells (►Fig. 4A). This effect was particularly evident at doses of PMPs higher than 20 µg/mL, which are in the range of the microparticles concentration found in the plasma of cancer patients. 23 Both preparations of PMPs were essentially ineffective on the migration of MCF7 cells (►Fig. 4B). Finally, we analyzed the effect of PMPs on the ability of cancer cells to invade extracellular matrix, through a Matrigel-coated transwell assay. ►Fig. 4C shows that MDA-MB-231-induced PMPs promoted a significant potentiation of the invasive ability of MDA-MB-231. Again, MCF7-induced PMPs displayed no effects. No stimulation of invasion propensity of MCF7 was observed when MCF7 cells were incubated with both types of 
Discussion
In this article, we demonstrated for the first time that breast cancer cells can efficiently induce the release of microparticles from blood platelets and that the released microparticles can signal back to cancer cells to alter their invasive properties.
The ability of cancer cells to bind and activate platelets has been widely investigated.
1,24 Previous "in vitro" studies have documented the peculiar and delayed kinetics of cancer cellinduced platelet aggregation compared with physiological agonists, but still the mechanism, the signal transduction pathways, and the receptors involved in this process remain poorly characterized. Nevertheless, platelet aggregation induced by cancer cells is considered an important step for the metastatic process, as it can facilitate tumor cell survival in the circulation and favor extravasation. 4 Similarly, the release of microparticles from platelets has emerged as a novel strategy for intercellular communication, as PMPs are known to carry several biological signals that can be efficiently transferred to target cells. 7, 8 Our study moves a step forward in understanding the complex interplay between cancer cells and blood platelets, as it identifies a previously unrecognized mechanism by which cancer cells exploit blood platelets to generate PMPs able to increase their metastatic potential. The use of two different breast cancer cell lines characterized by a different metastatic phenotype also provided multiple evidences that this novel interplay between cancer cells and blood platelets is rather complex and is strongly dependent on the characteristic of the cancer cells. Both MDA-MB-231 and MCF7 cells were able to cause platelet aggregation and the release of PMPs. By contrast, cancer cell-induced platelet aggregation is not accompanied by the release of microparticles from cancer cells. Nevertheless, different cancer cells, albeit able to induce comparable platelet aggregation, are differently potent in stimulating PMPs release. This is also very well outlined in this study, as we document that MDA-MB-231 cells are more potent than MCF7 cells in inducing PMPs release, although both kind of cells cause comparable platelet aggregation. Therefore, tumor cell-induced platelet aggregation is necessary, but clearly not sufficient to induce PMPs release. The precise understanding of the mechanism for cancer cellinduced release of PMPs is largely hampered by the current poor characterization of the mechanism supporting cancer cell-induced platelet aggregation. How these events are linked and what is the role played in both processes by cell-cell contact events, rather than release of soluble factors with paracrine activity, deserve further detailed investigations. Nevertheless, the different efficiency of MDA-MB-231 and MCF7 cells to induce PMPs release is suggestive that, when released from solid tumor into the bloodstream, differently aggressive cancer cells may produce variable platelet responses.
An additional important finding of our study is that PMP released upon cancer cells interaction with platelets acts as regulators of cancer cells themselves. Few previous studies have indicated that PMPs released by platelet activation by classical agonists such as thrombin, which occurs during a hemostatic or thrombotic event, are able to activate cancer cells. 9, 18, 19, 25 Here we show that cancer cells are active players in a novel positive feedback mechanism, as they are not only targets of PMPs but also promoters of their release independently of platelet implication in hemostasis or thrombosis. Interestingly, only MDA-MB-231 but not MCF7 cells were able to interact with, and rapidly internalize, PMPs. This indicates that the ability to bind PMPs is not a general feature of tumor cells, but depends on the cell type. The fact that MCF7 cells induce platelet aggregation and the release of PMPs, but are unable to subsequently bind them, also indicates that the ability of cancer cells to bind PMPs is clearly distinct from the ability to bind intact platelets, and suggests significant differences in receptor recognition. However, how MDA-MB-231 cells bind to PMPs is still unclear. Our evidence indicates that this interaction does not involve either integrin αIIbβ3 or P-selectin. However, the sensitivity to heparin suggests the implication of a still unknown carbohydrate-based recognition mechanism. Further studies are certainly required for a precise characterization of the receptors involved.
PMPs released upon platelet stimulation with MDA-MB-231 or MCF7 cells are internalized by MDA-MB-231 cells with a similar efficiency. However, only PMPs generated by platelet interaction with MDA-MB-231, but not with MCF7 cells, stimulate the phosphorylation of selected signaling proteins and increase migration and invasion of MDA-MB-231 cells. Therefore, although different types of cancer cells can induce PMPs release, only some subsets of released PMPs display prometastatic effects on the generating cancer cells. These findings suggest that PMPs released by platelets in response to different types of cancer cells are intrinsically different from their ability to alter the migratory phenotype of the target cells. This is consistent with previous studies indicating that, when platelets are stimulated with physiological agonists, the composition of released PMPs may vary depending on the generating stimulus. 7 It is important to outline that, in our functional assays, identical amounts of isolated PMPs recovered by centrifugation from the platelet releasate have been used. Although the possibility that some large macromolecular complexes coprecipitate with the recovered PMPs cannot be completely rule out, the differential effects on cell migration and invasion cannot be ascribed to the presence of unidentified soluble agonists released by stimulated platelets. It is also very important to note that the stimulation of MDA-MB-231 cells migration was observed in response to a range of PMPs concentration comparable to that measured in the plasma of cancer patients, 21 indicating that the effect may be physiologically relevant.
In conclusion, our results identify a novel positive feedback mechanism by which some cancer cells may increase their own aggressiveness while circulating in the bloodstream, by inducing the release of specific PMPs. It is conceivable that, by interacting with platelets and inducing their aggregation, cancer cells generate a prometastatic niche in which high concentrations of PMPs may signal back to the generating cancer cell to alter its phenotype. The nature of the circulating cancer cell dictates the relevance of this prometastatic feedback. The identification of the molecular determinants responsible for cancer cell-PMPs interaction may be useful to develop novel pharmacological strategy to limit the efficacy of such prometastatic loop.
Although further studies are certainly required to map the ability of cancer cells from different tumors to stimulate PMPs release and to become their biological targets, our results document a novel and unexpected mechanism supporting platelet-assisted cancer metastasis.
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